🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Clinical trials save lives!

BTK inhibitors! I have mainly been using zanubrutinib. Biggest issue is neutropenia but usually not severe enough to necessitate dose reduction.

🙌🙌 Brilliant presentation at BSH - Haematology ASM by Manchester Cancer Research Centre NIHR Manchester Biomedical Research Centre Dr John Radford on long-term f/u for early-stage Hodgkin #lymphoma pts treated on the RAPID trial. ➡️➡️ OS remains excellent in both groups (consolidative radiation & no RT) @ 15 years (92-94%). #BSH2025

Noted! #LEx26

Ya escucharon en último episodio de #Fase3Podcast ? Astrid Pavlovsky y Anna Sureda se lucen analizando el potencial impacto que el ensayo clínico STARGLO tendrá en nuestra región.

Imperdible episodio! Cual es el rol de la combinación de ac biespecificos +quimioterapia en DCGB R/R en nuestra región con escaso acceso a cart y donde encaja en el resto del mundo donde todas las opciones están disponibles?

Anna Sureda y Astrid Pavlovsky discuten el STARGLO. Es el nuevo SOC en 2da línea para pacientes con LDCGB no candidatos TACPH? Y de yapa nos cuentan como llegaron a escribir la editorial del artículo. Un equipazo! Lymphoma Experience Guilherme Perini, MD Joaquín Díaz-Schmidt

This episode with Manni Mohyuddin is more on trend than ever with the starglo controversy: a trial aiming FDA approval but recruiting poorly in the US. Different treatment options approved there made the control arm less attractive for us centers? Lymphoma Experience Guilherme Perini, MD Joaquín Díaz-Schmidt

The FDA obviously isn’t required to do so, but it could take into account that such approvals are viewed globally for this type of intervention, particularly in countries where there is no access to CAR-T. In Latin America, it will complicate matters for all of us.

Conheça os convidados internacionais já confirmados no Board Review: XIX Curso de Revisão em Hematologia e Hemoterapia do Hospital Israelita Albert Einstein. Os usuários Hematolog têm 50% de desconto no valor. Aproveite!  Acesse: bit.ly/43OnVZ6

So happy to be part of the Board Review!! See you soon in Sao Paulo 🤗

Total intrigued by these results of treatment benefit across cell of origin subgroups in the polargo trial in contrast to polarix. Do you have an hypothesis Ash Alizadeh, MD/PhD 🇺🇸? #ICML18 #ICML2025 Lymphoma Experience

Directamente desde ICML-18 en Lugano, Suiza, debuta el segmento: “Tres cervezas y un abstract”, esta vez discutiendo los resultados del ensayo “POLARGO” y la muerte del R-GemOx. Se recomienda acompañar de una cerveza helada. Laura Korin Guilherme Perini, MD Joaquín Díaz-Schmidt #ICML18

This should play a key role in lowering obstacles to access! LATAM has struggled with this! Daniel Ernst Nicolás Triantafilo C. Lymphoma Experience